HK1096392A1 - Substituted heterocycles - Google Patents

Substituted heterocycles

Info

Publication number
HK1096392A1
HK1096392A1 HK07103474.2A HK07103474A HK1096392A1 HK 1096392 A1 HK1096392 A1 HK 1096392A1 HK 07103474 A HK07103474 A HK 07103474A HK 1096392 A1 HK1096392 A1 HK 1096392A1
Authority
HK
Hong Kong
Prior art keywords
substituted heterocycles
heterocycles
substituted
medicaments
asthma
Prior art date
Application number
HK07103474.2A
Other languages
English (en)
Inventor
Marc Stadler
Stephan Seip
Hartwig Mueller
Anke Mayer-Bartschmid
Michael-Alexander Bruening
Jordi Benet-Buchholz
Hiroko Togame
Reiko Dodo
Peter Reinemer
Kevin Bacon
Kinji Fuchikami
Satoko Matsukawa
Klaus Urbahns
Original Assignee
Intermed Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermed Discovery Gmbh filed Critical Intermed Discovery Gmbh
Publication of HK1096392A1 publication Critical patent/HK1096392A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10Nitrogen as only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
HK07103474.2A 2003-02-14 2007-03-30 Substituted heterocycles HK1096392A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03003495 2003-02-14
EP03007594 2003-04-02
PCT/EP2004/001097 WO2004071382A2 (en) 2003-02-14 2004-02-06 Substituted heterocycles

Publications (1)

Publication Number Publication Date
HK1096392A1 true HK1096392A1 (en) 2007-06-01

Family

ID=32870763

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103474.2A HK1096392A1 (en) 2003-02-14 2007-03-30 Substituted heterocycles

Country Status (16)

Country Link
US (2) US20060229353A1 (ja)
EP (1) EP1597262B1 (ja)
JP (1) JP4795931B2 (ja)
KR (1) KR20050098928A (ja)
CN (1) CN1845925B (ja)
AT (1) ATE448232T1 (ja)
AU (1) AU2004212296B2 (ja)
BR (1) BRPI0407234A (ja)
CA (1) CA2515940C (ja)
DE (1) DE602004024037D1 (ja)
ES (1) ES2336562T3 (ja)
HK (1) HK1096392A1 (ja)
IL (1) IL169897A0 (ja)
IN (1) IN228043B (ja)
MX (1) MX272108B (ja)
WO (1) WO2004071382A2 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4395549B2 (ja) 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP2441767B1 (en) * 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamides and methods for use thereof
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、[3.2.0]複素環式化合物およびそれらの類縁体の使用
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1812443A2 (en) 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
EA200700286A1 (ru) * 2004-07-12 2007-08-31 Байер Кропсайенс Аг Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
ES2396762T3 (es) 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
CA2590334A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2006118973A2 (en) * 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
KR20080109071A (ko) 2006-04-06 2008-12-16 니리어스 파마슈티컬즈, 인코퍼레이션 살리노스포라마이드 a 및 그의 유도체들의 전합성
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
EP2262812A2 (en) 2008-03-07 2010-12-22 Nereus Pharmaceuticals, Inc. Total synthesis of salinosporamide a and analogs thereof
CN102089312A (zh) * 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
CA2853822A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
JP6486826B2 (ja) 2012-10-01 2019-03-20 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3339291A1 (en) 2016-12-22 2018-06-27 Vita Api Proteasome inhibiting ss-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群

Also Published As

Publication number Publication date
CN1845925B (zh) 2010-11-03
EP1597262B1 (en) 2009-11-11
WO2004071382A3 (en) 2005-01-06
CN1845925A (zh) 2006-10-11
BRPI0407234A (pt) 2006-01-31
DE602004024037D1 (de) 2009-12-24
EP1597262A2 (en) 2005-11-23
US20060229353A1 (en) 2006-10-12
AU2004212296B2 (en) 2010-06-17
MXPA05008478A (es) 2005-10-18
ATE448232T1 (de) 2009-11-15
KR20050098928A (ko) 2005-10-12
MX272108B (es) 2009-11-25
WO2004071382A2 (en) 2004-08-26
ES2336562T3 (es) 2010-04-14
CA2515940A1 (en) 2004-08-26
US20110015248A1 (en) 2011-01-20
IL169897A0 (en) 2007-07-04
IN2005DE03350A (ja) 2007-06-01
JP2006517934A (ja) 2006-08-03
CA2515940C (en) 2011-12-06
JP4795931B2 (ja) 2011-10-19
IN228043B (ja) 2009-02-13
AU2004212296A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
HK1096392A1 (en) Substituted heterocycles
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
UA85559C2 (en) Aminobenzophenone compounds
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
TW200510343A (en) Substituted dihydroquinazolines
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2003080582A3 (de) Fredericamycin-derivate
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
TW200621799A (en) Acylated nonadepsipeptides II
TW200700411A (en) Heterocyclylamide-substituted imidazoles
HK1106253A1 (en) Desoxo-nonadepsipeptides
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE502007004579D1 (de) Aryl-substituierte heterozyklen und ihre verwendung
ATE455789T1 (de) Substituierte nonadepsipeptide
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
SE0300457D0 (sv) Novel compounds
TW200504051A (en) Novel acridine derivatives and their use as medicaments

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150206